Latest News

Filters close
Newswise: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Released: 29-May-2020 10:30 AM EDT
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
University of Texas M. D. Anderson Cancer Center

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

Newswise: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
Released: 29-May-2020 10:20 AM EDT
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
University of Texas M. D. Anderson Cancer Center

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

Released: 29-May-2020 10:15 AM EDT
Next Frontier in Bacterial Engineering
Harvard Medical School

A new technique overcomes a serious hurdle in the field of bacterial design and engineering Researchers develop method to identify proteins that enable highly efficient bacterial design Approach has potential to boost efforts in bacterial design to tackle infectious diseases, bacterial drug resistance, environmental cleanup and more

Newswise: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
Released: 29-May-2020 10:05 AM EDT
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
University of Texas M. D. Anderson Cancer Center

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

access_time Embargo lifts in 2 days
Embargo will expire: 2-Jun-2020 11:00 AM EDT Released to reporters: 29-May-2020 10:05 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 2-Jun-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Daya Bay Reactor Experiment Continues to Generate Data
Released: 29-May-2020 10:00 AM EDT
Daya Bay Reactor Experiment Continues to Generate Data
Lawrence Berkeley National Laboratory

Largely unaffected by the pandemic, the Daya Bay reactor neutrino experiment in Shenzen, China, has continued to pump data to remote supercomputers for analyses.

Newswise:Video Embedded newswise-expert-panels-on-covid-19-pandemic-notable-excerpts-quotes-and-videos-available
VIDEO
Released: 29-May-2020 9:50 AM EDT
Newswise Expert Panels on COVID-19 Pandemic: Notable excerpts, quotes and videos available
Newswise

Newswise is hosting a series of Expert Panels discussion unique aspects of the COVID-19 Outbreak. This tip sheet includes some notable quotes from the panelists.

Newswise: COVID-19 Healthcare Coalition Launches COVID-19 Decision Support Dashboard
Released: 29-May-2020 9:00 AM EDT
COVID-19 Healthcare Coalition Launches COVID-19 Decision Support Dashboard
COVID-19 Healthcare Coalition

The new COVID-19 Decision Support Dashboard synthesizes large amounts of complex, essential data into easy-to-use key findings for public and private-sector leaders navigating the “reopening” of communities and businesses.


Showing results

4110 of 10

close
0.20836